

# M Hong Nguyen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/6493977/m-hong-nguyen-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

95 papers	4,804 citations	32 h-index	69 g-index
100 ext. papers	6,114 ext. citations	5.7 avg, IF	6.15 L-index

#	Paper	IF	Citations
95	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, e1-e60	11.6	1274
94	Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	245
93	Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant <i>Klebsiella pneumoniae</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	239
92	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 63, 433-42	11.6	216
91	Performance of <i>Candida</i> real-time polymerase chain reaction, $\beta$ -D-glucan assay, and blood cultures in the diagnosis of invasive candidiasis. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 54, 1240-8	11.6	207
90	Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infections: Clinical Effectiveness and Evolution of Resistance. <i>Clinical Infectious Diseases</i> , <b>2017</b> , 65, 110-120	11.6	167
89	Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. <i>Intensive Care Medicine</i> , <b>2020</b> , 46, 1524-1535	14.5	149
88	Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	130
87	Coronavirus Disease 2019, Superinfections, and Antimicrobial Development: What Can We Expect?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 2736-2743	11.6	124
86	Mutations in That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum $\beta$ -Lactamases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	114
85	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 1678-1686	11.6	98
84	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2020</b> , 6,	5.6	88
83	Effects of <i>Klebsiella pneumoniae</i> carbapenemase subtypes, extended-spectrum $\beta$ -lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant <i>K. pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 5793-7	5.9	87
82	Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	86
81	Carbapenem-resistant <i>Klebsiella pneumoniae</i> strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 4443-51	5.9	82
80	Abdominal candidiasis is a hidden reservoir of echinocandin resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 7601-5	5.9	77
79	Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Carbapenemase-Producing : A Case Report and Review of Literature. <i>Open Forum Infectious Diseases</i> , <b>2017</b> , 4, ofx101	1	74

78	Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant <i>Pseudomonas aeruginosa</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3227-31	5.9	71
77	Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible <i>Klebsiella pneumoniae</i> Isolates with Variant KPC-3 Carbapenemases. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	63
76	T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, iv2-iv5	5.1	51
75	Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	48
74	Rapid Detection of FKS-Associated Echinocandin Resistance in <i>Candida glabrata</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 6573-6577	5.9	47
73	Invasive Aspergillosis as an Under-recognized Superinfection in COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa242	1	43
72	Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 667-671	11.6	42
71	Effects of KPC Variant and Porin Genotype on the Activity of Meropenem-Vaborbactam against Carbapenem-Resistant. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	42
70	Efficacy of T2 Magnetic Resonance Assay in Monitoring Candidemia after Initiation of Antifungal Therapy: the Serial Therapeutic and Antifungal Monitoring Protocol (STAMP) Trial. <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	41
69	Estimating the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in the United States Using Antibiotic Prescription Data. <i>Open Forum Infectious Diseases</i> , <b>2019</b> , 6, ofz344	1	38
68	Rate of FKS Mutations among Consecutive <i>Candida</i> Isolates Causing Bloodstream Infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 7465-70	5.9	36
67	PRO: The COVID-19 pandemic will result in increased antimicrobial resistance rates. <i>JAC-Antimicrobial Resistance</i> , <b>2020</b> , 2, dlaa049	2.9	36
66	Association between the Presence of Aminoglycoside-Modifying Enzymes and In Vitro Activity of Gentamicin, Tobramycin, Amikacin, and Plazomicin against <i>Klebsiella pneumoniae</i> Carbapenemase- and Extended-Spectrum- $\beta$ -Lactamase-Producing Enterobacter Species. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 5208-14	5.9	34
65	Delinking CARD9 and IL-17: CARD9 Protects against <i>Candida tropicalis</i> Infection through a TNF- $\beta$ -Dependent, IL-17-Independent Mechanism. <i>Journal of Immunology</i> , <b>2015</b> , 195, 3781-92	5.3	32
64	Doripenem, gentamicin, and colistin, alone and in combinations, against gentamicin-susceptible, KPC-producing <i>Klebsiella pneumoniae</i> strains with various ompK36 genotypes. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 3521-5	5.9	32
63	Verification of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Susceptibility Testing Methods against Carbapenem-Resistant Enterobacteriaceae and <i>Pseudomonas aeruginosa</i> . <i>Journal of Clinical Microbiology</i> , <b>2018</b> , 56,	9.7	32
62	Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2018</b> , 4,	5.6	31
61	Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3187-92	5.9	31

60	Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. <i>Intensive Care Medicine</i> , <b>2021</b> , 47, 819-834	14.5	30
59	<i>Candida glabrata</i> intra-abdominal candidiasis is characterized by persistence within the peritoneal cavity and abscesses. <i>Infection and Immunity</i> , <b>2014</b> , 82, 3015-22	3.7	29
58	Effects of Isavuconazole on the Plasma Concentrations of Tacrolimus among Solid-Organ Transplant Patients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	29
57	Bacterial Superinfections Among Persons With Coronavirus Disease 2019: A Comprehensive Review of Data From Postmortem Studies. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab065	1	28
56	Invasive mould disease in fatal COVID-19: a systematic review of autopsies. <i>Lancet Microbe</i> , <b>2021</b> , 2, e405-e414	22.2	27
55	Antibiotic Consumption and Stewardship at a Hospital outside of an Early Coronavirus Disease 2019 Epicenter. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	26
54	Doripenem MICs and ompK36 porin genotypes of sequence type 258, KPC-producing <i>Klebsiella pneumoniae</i> may predict responses to carbapenem-colistin combination therapy among patients with bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2015</b> , 59, 1797-801	5.9	24
53	Impact of the Coronavirus Disease 2019 Pandemic on Outpatient Antibiotic Prescriptions in the United States. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa575	1	23
52	Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	21
51	Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 73, 416-426	11.6	19
50	Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	18
49	Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> ,	5.9	17
48	KPC-producing <i>Klebsiella pneumoniae</i> strains that harbor AAC(6)-Ib exhibit intermediate resistance to amikacin. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 7597-600	5.9	16
47	Pharmacokinetics of Azole Antifungals in Cystic Fibrosis. <i>Mycopathologia</i> , <b>2018</b> , 183, 139-150	2.9	15
46	Coordination of <i>Candida albicans</i> Invasion and Infection Functions by Phosphoglycerol Phosphatase Rhr2. <i>Pathogens</i> , <b>2015</b> , 4, 573-89	4.5	13
45	Pharmacokinetics of Posaconazole Suspension in Lung Transplant Patients with and without Cystic Fibrosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3558-62	5.9	13
44	Highly Dynamic and Specific Phosphatidylinositol 4,5-Bisphosphate, Septin, and Cell Wall Integrity Pathway Responses Correlate with Caspofungin Activity against <i>Candida albicans</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2016</b> , 60, 3591-600	5.9	12
43	Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2018</b> , 62,	5.9	11

42	Impact of Revised Infectious Diseases Society of America and Society for Healthcare Epidemiology of America Clinical Practice Guidelines on the Treatment of Clostridium difficile Infections in the United States. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 1944-1949	11.6	11
41	Coronavirus Disease 2019-Associated Invasive Fungal Infection. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab510	1	10
40	Population Pharmacokinetics of Intravenous Isavuconazole in Solid-Organ Transplant Recipients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2020</b> , 64,	5.9	9
39	Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2021</b> , 65,	5.9	9
38	Invasive Candidiasis in Various Patient Populations: Incorporating Non-Culture Diagnostic Tests into Rational Management Strategies. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2016</b> , 2,	5.6	9
37	Pharmacodynamics of Ceftazidime plus Avibactam against KPC-2-Bearing Isolates of in a Hollow Fiber Infection Model. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> , 63,	5.9	8
36	Buying Time: The AMR Action Fund and the State of Antibiotic Development in the United States 2020. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa464	1	8
35	When are extreme daily returns not lottery? At earnings announcements!. <i>Journal of Financial Markets</i> , <b>2018</b> , 41, 92-116	2.1	7
34	Mutational analysis of essential septins reveals a role for septin-mediated signaling in filamentation. <i>Eukaryotic Cell</i> , <b>2014</b> , 13, 1403-10		7
33	Achievement of clinical isavuconazole blood concentrations in transplant recipients with isavuconazonium sulphate capsules administered via enteral feeding tube. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 3023-3028	5.1	7
32	Trends in Outpatient Antibiotic Prescriptions in the United States During the COVID-19 Pandemic in 2020. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2126114	10.4	6
31	Invasive Mould Disease in Fatal COVID-19: A Systematic Review of Autopsies		5
30	Politics and liquidity. <i>Journal of Financial Markets</i> , <b>2018</b> , 38, 1-13	2.1	5
29	Diagnostic Modalities for Invasive Mould Infections among Hematopoietic Stem Cell Transplant and Solid Organ Recipients: Performance Characteristics and Practical Roles in the Clinic. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2015</b> , 1, 252-276	5.6	4
28	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac078	1	3
27	Genetic diversity of clinical and environmental Mucorales isolates obtained from an investigation of mucormycosis cases among solid organ transplant recipients. <i>Microbial Genomics</i> , <b>2020</b> , 6,	4.4	3
26	It's worse than we thought: the US market for novel Gram-negative antibiotics. <i>Lancet Infectious Diseases</i> , <b>2020</b> , 20, 1009-1010	25.5	3
25	Does investor attention matter for market anomalies?. <i>Journal of Behavioral and Experimental Finance</i> , <b>2021</b> , 29, 100451	6.1	3

24	Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 649675	4.9	3
23	Air pollution and behavioral biases: Evidence from stock market anomalies. <i>Journal of Behavioral and Experimental Finance</i> , <b>2021</b> , 29, 100441	6.1	3
22	Do Climate Risks Matter for Green Investment?. <i>Journal of International Financial Markets, Institutions and Money</i> , <b>2021</b> , 75, 101438	3.6	3
21	Invasive Pulmonary Aspergillosis Complicating Noninfluenza Respiratory Viral Infections in Solid Organ Transplant Recipients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab478	1	2
20	Epidemiologic and Microbiologic Characteristics of Hospitalized Patients Co-colonized With Multiple Species of Carbapenem-Resistant Enterobacteriaceae in the United States. <i>Open Forum Infectious Diseases</i> , <b>2020</b> , 7, ofaa386	1	2
19	Molecular epidemiology, natural history and long-term outcomes of multi-drug resistant Enterobacteriales colonization and infections among solid organ transplant recipients. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	2
18	Country governance and international equity returns. <i>Journal of Banking and Finance</i> , <b>2021</b> , 122, 105986	2.6	2
17	PCR-Based Methods for the Diagnosis of Invasive Candidiasis: Are They Ready for Use in the Clinic?. <i>Current Fungal Infection Reports</i> , <b>2018</b> , 12, 71-77	1.4	1
16	Pathogenesis of Invasive Pulmonary Aspergillosis in Transplant Recipients. <i>Current Fungal Infection Reports</i> , <b>2017</b> , 11, 148-157	1.4	1
15	Systemic Candidiasis: Candidemia and Deep-Organ Infections	429-441	1
14	Bribe or die: gender differences in entrepreneurship in emerging markets. <i>Applied Economics</i> , <b>2021</b> , 53, 2170-2191	1.6	1
13	Sequence type-258 carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates in which ceftazidime-avibactam resistance emerged are not hypermutators. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2020</b> , 96, 114954	2.9	1
12	Empyema Thoracis at Two Academic Medical Centers: New Insights Into Treatment and Outcomes. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa656	1	1
11	Reply to Turner. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, 2065-2066	11.6	1
10	Bank performance during the credit crisis: evidence from Asia-Pacific countries. <i>Applied Economics Letters</i> , 1-14	1	1
9	Climate events and return comovement. <i>Journal of Financial Markets</i> , <b>2022</b> , 100731	2.1	1
8	A 62-year-old male heart transplant recipient with progressive hypoxia. <i>Chest</i> , <b>2011</b> , 139, 954-957	5.3	0
7	Fungal infections in lung transplantation.. <i>Journal of Thoracic Disease</i> , <b>2021</b> , 13, 6695-6707	2.6	0

6	Coronavirus Disease 2019-Associated Pulmonary Aspergillosis: Reframing the Debate.. <i>Open Forum Infectious Diseases</i> , <b>2022</b> , 9, ofac081	1	0
5	What Is New in Candida Infections? T2Candida, Antifungal Stewardship, and Candida auris. <i>Current Treatment Options in Infectious Diseases</i> , <b>2020</b> , 12, 1-12	1	
4	Discordance Among Antibiotic Prescription Guidelines Reflects a Lack of Clear Best Practices. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofaa571	1	
3	Transcriptional Profiling Within Biliary Fluid From a Patient With Cholangitis, Before and After Antifungal Treatment and Surgical Drainage. <i>Open Forum Infectious Diseases</i> , <b>2016</b> , 3, ofw120	1	
2	Antibacterial Drug Development Trends in the United States from 1980-2019: Agents Active Against Carbapenem-resistant Gram-negative Bacteria as Case Study. <i>Clinical Infectious Diseases</i> , <b>2021</b> , 72, e437-e438	11.6	
1	Do accounting information and market environment matter for cross-asset predictability?. <i>Accounting and Finance</i> , <b>2021</b> , 61, 4389-4434	1.9	